Suneva Medical Announces 90-day Results From Regenica® Rejuvenating Dual Serum Clinical Study
-- Anti-aging serum created with the most advanced growth factor technology shown to reduce the appearance of fine lines and coarse wrinkles, and improve skin radiance
-- Statistically significant improvements were seen as early as 14 days, with continued improvement seen through 90 days(1)
-- Primary efficacy endpoint was met for the investigator-assessed rating for overall facial skin appearance(1)
SAN DIEGO, June 22, 2016 /PRNewswire/ -- Suneva Medical, Inc., a privately-held aesthetics company, today announced the results of its 90-day clinical study that evaluated Regenica® Rejuvenating Dual Serum. In the study, statistically significant improvements were reported as early as 14 days, with continued improvement seen at 90 days in parameters that included the reduction in the appearance of fine lines, an increase in brightness, skin radiance and improved appearance of skin firmness and blotchiness. The study showed 95 percent overall patient satisfaction and 87 percent of patients would recommend the serum to a friend.1
Regenica® Rejuvenating Dual Serum is the flagship offering within the Regenica® skin care line. Backed by sound science and clinical data, the new serum represents a revolutionary breakthrough in skin care and was specifically developed to improve the appearance of skin tone, texture and brightness, as well as reduce the appearance of fine lines and wrinkles. The powerful, dual chamber serum is created using the most advanced growth factor technology that combines a 95 percent concentration of MRCx™—a unique, proprietary blend of growth factors, cytokines and proteins—and anti-aging ingredients including advanced copper peptides, amino acids, antioxidants and plant-based extracts.
"In a short application time, statistically significant improvements were observed in the appearance of fine lines, firmness and overall skin radiance. Corneometry, a quantitative measure of skin hydration, showed statistically significant results as early as day 14 and continued through day 90," said Dr. Zoe Draelos, clinical and research dermatologist and the study's lead investigator.
The 90-day clinical study evaluated 40 women who were asked to use Regenica® Rejuvenating Dual Serum on their entire face, twice daily. Patients reported a reduction in fine lines as early as 14 days, with continued improvement seen through the duration of the study. A reduction in the appearance of coarse wrinkles and blotchiness was also reported. The study showed an increase in brightness and skin radiance, and improved appearance of skin firmness and skin elasticity. Patients reported an improvement in skin health and skin rejuvenation and 95 percent were satisfied with Regenica® Rejuvenating Dual Serum. When asked about the product's color, 100 percent of patients were satisfied; over 95 percent were satisfied with the texture and smell. The primary efficacy endpoint was met for the investigator-assessed rating for overall facial skin appearance.1
"Regenica® is the result of decades of research in regenerative science and the outcomes of this 90-day study further emphasize its effectiveness," said Nicholas L. Teti, Jr., Chairman and Chief Executive Officer at Suneva Medical. "As growth factor skincare rises in popularity, patients can confidently turn to Regenica® Rejuvenating Dual Serum for anti-aging benefits that are backed by sound science."
The popular Regenica® product line includes Regenica® Rejuvenating Dual Serum, Regenica® Replenishing Crème, Regenica® Renew SPF 15, Regenica® Revitalizing Eye Crème, Regenica® Repair Complex and Regenica® Recovery Gel. To learn more about Regenica® or find a provider, visit www.regenica.com. Follow Regenica® on Facebook: facebook.com/regenicaskincare, Twitter: @RegenicaSkin and Instagram: RegenicaSkincare.
Regenica® and MRCx™ are trademarks of Suneva Medical, Inc.
About Suneva Medical, Inc.
Suneva Medical is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. The innovative aesthetics leader markets Bellafill®, the only dermal filler on the market that is approved by the U.S. Food and Drug Administration for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. The company markets Bellafill® in the U.S., Canada and Hong Kong; ArteFill® in South Korea; Regenica® skincare in the U.S., Canada and Hong Kong; and ReFissa® tretinoin cream in the U.S. ArteFill® was rebranded to Bellafill® in the U.S. to reflect the transformational outcomes this unique product can provide to patients seeking correction of their acne scars and nasolabial folds. For more information, visit www.sunevamedical.com.
1Suneva Medical, data on file
Photo - http://photos.prnewswire.com/prnh/20160622/382174
Logo - http://photos.prnewswire.com/prnh/20150227/178494LOGO
SOURCE Suneva Medical, Inc.
Share this article